NYSE: PACSPacs Group Inc Stock
$37.81-1.10 (-2.83%)
Updated Feb 13, 2026
PACS Price
$37.81
Fair Value Price
N/A
Market Cap
$5.92B
52 Week Low
$7.50
52 Week High
$43.08
P/E
34.69x
P/B
6.8x
P/S
0.42x
PEG
0.85x
Dividend Yield
N/A
Revenue
$5.14B
Earnings
$169.04M
Gross Margin
14.2%
Operating Margin
5.63%
Profit Margin
3.3%
Debt to Equity
5.45
Operating Cash Flow
$472M
Beta
0.67
Next Earnings
Feb 25, 2026
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PACS's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Care Facility
Industry Rating
A
PACS
Ranked#19 of 41
Ranked#19 of 41
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $21.52 | A | |
| $7.93 | A | |
| $11.16 | A |
Be the first to know about important PACS news, forecast changes, insider trades & much more!
PACS News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PACS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PACS ($37.81) is trading above its intrinsic value of $22.96, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PACS is good value based on its earnings relative to its share price (34.69x), compared to the US market average (43.92x)
P/E vs Market Valuation
PACS is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more PACS due diligence checks available for Premium users.
Valuation
PACS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
34.69x
Industry
16.98x
Market
43.92x
PACS is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PACS is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
PACS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.8x
Industry
5.95x
PACS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PACS price to earnings growth (PEG)
For valuing profitable companies with growth potential
PACS is good value based... subscribe to Premium to read more.
PEG Value Valuation
PACS's financial health
Profit margin
Revenue
$1.3B
Net Income
$52.4M
Profit Margin
3.9%
PACS's Earnings (EBIT) of $289.10M... subscribe to Premium to read more.
Interest Coverage Financials
PACS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$5.6B
Liabilities
$4.7B
Debt to equity
5.45
PACS's short-term liabilities ($1.20B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PACS's long-term liabilities ($3.55B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PACS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$204.8M
Investing
-$97.1M
Financing
-$46.3M
PACS's operating cash flow ($472.20M)... subscribe to Premium to read more.
Debt Coverage Financials
PACS vs Medical Care Facility Stocks
Pacs Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.